Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice.
Arteaga
Carlos L
CL
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6307, USA. carlos.arteaga@vanderbilt.edu
Baselga
Jose
J
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000592:standards*; D019468:Disease Management; D016503:Drug Delivery Systems / Q000379:methods*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D012107:Research Design / Q000592:standards*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D066246:ErbB Receptors